A company, AdverseEvents, is making a name for itself by analysing and publish the side-effects reported to the FDA as caused by new drugs on the market.
Already, new type-2 diabetes drugs have come under the microscope. Going by names such as DPP-4, GLP-1 and SLGT2 they have produced complaints of serious gut problems, renal and urinary infections and even links to pancreatic and thyroid cancers.
In a press release Brian Overstreet, CEO of AdverseEvents, said “The only way to fully review a drug’s safety is to track and monitor side effects as the general population begins utilizing the drugs on an ongoing basis, in real-world circumstances.”
